| Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART … C Le Pechoux, N Pourel, F Barlesi, D Lerouge, D Antoni, B Lamezec, ... The Lancet Oncology 23 (1), 104-114, 2022 | 193 | 2022 |
| LBA3_PR An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer … C Le Pechoux, N Pourel, F Barlesi, C Faivre-Finn, D Lerouge, G Zalcman, ... Annals of Oncology 31, S1178, 2020 | 124 | 2020 |
| Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk B Pistilli, A Paci, AR Ferreira, A Di Meglio, V Poinsignon, A Bardet, ... Journal of Clinical Oncology 38 (24), 2762, 2020 | 96 | 2020 |
| Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised … P Pautier, A Italiano, S Piperno-Neumann, C Chevreau, N Penel, N Firmin, ... The Lancet Oncology 23 (8), 1044-1054, 2022 | 48 | 2022 |
| Impact of COVID-19 on healthcare organisation and cancer outcomes A Bardet, AM Fraslin, J Marghadi, I Borget, M Faron, C Honoré, ... European Journal of Cancer 153, 123-132, 2021 | 32 | 2021 |
| Quality‐of‐life assessment in French patients with metastatic melanoma in real life M Kandel, S Dalle, A Bardet, C Allayous, L Mortier, C Dutriaux, B Guillot, ... Cancer 126 (3), 611-618, 2020 | 15 | 2020 |
| Characterization of depressive symptoms trajectories after breast cancer diagnosis in women in France C Charles, A Bardet, A Larive, P Gorwood, N Ramoz, E Thomas, A Viari, ... JAMA Network Open 5 (4), e225118-e225118, 2022 | 13 | 2022 |
| Delivering adapted physical activity by videoconference to patients with fatigue under immune checkpoint inhibitors: lessons learned from the PACTIMe-FEAS feasibility study C Charles, A Bardet, N Ibrahimi, O Aromatario, L Cambon, A Imbert, ... Journal of Telemedicine and Telecare 29 (9), 716-724, 2023 | 11 | 2023 |
| A retrospective study on the management of patients with rituximab refractory follicular lymphoma P Solal‐Céligny, P Leconte, A Bardet, J Hernandez, X Troussard British journal of haematology 180 (2), 217-223, 2018 | 11 | 2018 |
| Outcomes of patients with active cancer and COVID-19 in the intensive-care unit: a multicenter ambispective study H Plais, M Labruyère, T Creutin, P Nay, G Plantefeve, R Tapponnier, ... Frontiers in Oncology 12, 858276, 2022 | 10 | 2022 |
| Sequential or combined designs for Phase I/II clinical trials? A simulation study C Rossoni, A Bardet, B Geoerger, X Paoletti Clinical Trials 16 (6), 635-644, 2019 | 10 | 2019 |
| Development of a Decision-Aid Form (DAF) for the stratification of care in a French comprehensive cancer center, a tool to support identification of care goals L Vigouret-Viant, C Legoupil, A Bardet, C Laurent, M Ducreux, S Laurent, ... Annals of Palliative Medicine 11 (6), 1876887-1871887, 2022 | 5 | 2022 |
| A microsimulation model to assess the impact of SARS-CoV-2 on cancer outcomes, healthcare organization and economic burden A Bardet, A Fraslin, M Faron Congrès European society of medical oncology, 2020 | 5 | 2020 |
| Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study D Chaoui, S Choquet, L Sanhes, B Mahé, M Hacini, O Fitoussi, Y Arkam, ... Leukemia & lymphoma 58 (6), 1366-1375, 2017 | 5 | 2017 |
| 1170O An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer … C Le Pechoux, F Barlesi, N Pourel, C Faivre-Finn, D Lerouge, G Zalcman, ... Annals of Oncology 32, S939, 2021 | 4 | 2021 |
| Quality of surgery and RT in stage IIIN2 NSCLC: insights from the lung adjuvant radiotherapy trial Y Moukasse, N Pourel, D Lerouge, C Faivre-Finn, S Ramella, J Edwards, ... | 4 | 2020 |
| Association of adherence to endocrine therapy among patients with breast cancer and potential drug-drug interactions E Rassy, A Bardet, O Bougacha, L Gantzer, B Lekens, S Delaloge, ... JAMA Network Open 5 (12), e2244849-e2244849, 2022 | 3 | 2022 |
| An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC … C Le Pechoux, F Barlesi, N Pourel, C Faivre-Finn, D Lerouge, G Zalcman, ... | 3 | 2021 |
| An international randomized trial comparing post-operative radiotherapy (PORT) to no PORT, in patients with completely resected NSCLC and mediastinal N2 involvement C Le Péchoux, N Pourel, F Barlesi, C Faivre-Finn, D Lerouge, G Zalcman, ... ESMO, 2020 | 2 | 2020 |
| Bevacizumab exposure and tumor response in patients with platinum resistant epithelial ovarian cancer. J Michels, M Hamimed, Y Menu, C Balleyguier, F Ghiringhelli, JS Frenel, ... Journal of Clinical Oncology 41 (16_suppl), 3093-3093, 2023 | 1 | 2023 |
